Kaiser Health News | May 6, 2021
Regardless of what happens with the waiver, the tenor of international conversation about intellectual property rights puts pharmaceutical companies on notice, said Mara Pillinger, a senior associate in global health policy and governance at Georgetown’s O’Neill Institute for National and Global Health Law.
“Large parts of the world are not going to suffer with covid until [the industry] gets around to prioritizing them,” she said.